Human PILR-alpha quantitates human PILR-alpha in serum, plasma, supernatant. The assay will exclusively recognize both natural and recombinant human PILR-alpha.
Human PILR-alpha quantitates human PILR-alpha in serum, plasma, supernatant. The assay will exclusively recognize both natural and recombinant human PILR-alpha.
Dephosphorylation of SHP-1 mediated protein tyrosine residues is essential for the regulation of several cellular signaling pathways. The superfamily of inhibitory receptors has two types of limbs: tyrosine-based immunoreceptor-inhibitor receptors (TIM) and their non-ITIM-enactant counterparts. Control of cellular signaling via SHP-1 is thought to occur by balancing PILR alpha mediated inhibition with PILR beta mediated activation. This particular gene encodes the ITIM member of the receptor pair, which works in the inhibitory role. Cell signaling pathways are based on dynamic interaction between activation and inhibition processes. Dephosphorylation of SHP-1 mediated protein tyrosine residues is essential for the regulation of several cellular signaling pathways. The superfamily of inhibitory receptors has two types of limbs: tyrosine-based immunoreceptor-inhibitor receptors (TIM) and their non-ITIM-enactant counterparts. Control of cellular signaling via SHP-1 is thought to occur by balancing PILR alpha mediated inhibition with PILR beta mediated activation. These receptor genes similar to paired immunoglobulins are located in a tandem one-to-one orientation on chromosome 7. This particular gene encodes the ITIM member of the receptor pair, which plays the inhibitory role.
Sensitivity
Sensitivity of the dosage: 5.5 pg/ml.
Measurement range
Dose range: 5.5 to 1.500 pg/ml.
Duration of dosing
Total duration of dosing: 4 h 45 min.
Reproducibility
Coefficient of intradose variation < 10%, interdose < 12%.
Technical specifications
| General |
| Brand | Invitrogen |
| Supplier ref. (Fisher Scientific) | 17874130 |
| Specifications |
| Accession number | AV021745; FDF03 cell surface receiver; FDF03; PILR-alpha inhibitor receptor; alpha type 2 receptor related to paired immunoglobulin; alpha type 2 receptor related to paired immunoglobulin; alpha type 2 receptor related to paired immunoglobulin; Pilra |
| Dose range | 5.5 to 1.500 pg/ml |
| Sensitivity of the dosage | 5.5 pg/ml |
| Conjugate | Biotin |
| Product type | ELISA |
| Type of sample | Plasma, Serum, Surnatant |
| For use with (equipment) | Colorimetric microplate reader |
| Genetic identification (Enter) | Q9UKJ1 |
| Gene symbol(s) | PILRA |
| Coefficient of inter-dose variation | < 12% |
| Coefficient of intra-dose variation | < 10% |
| Contents of kits | 96-well pre-coated plate, standard, dosing diluent concentrate, biotinylated detection antibody, SAV-HRP, washing pad, chromogen, stop solution, adhesive plate lids |
| Marker or dye | HRP |
| Quantity | 10 x 96 tests |
| Regulatory status | Use exclusively for research |
| Target | PILRA |
| Test time | 1 h 20 min |
| Physical characteristics |
| Volume of sample | Supernatant, 50 μl; Serum, 50 μl; Plasma, 50 μl |
| Storage and shipping |
| Storage conditions | 2°C to 8°C |
| Total duration of dosing | 4 h 45 min |
Origin and customs
| Manufacturer ref. | EH368RBX10 |
|---|
| Country of origin | United States |
|---|
| HS customs code | 3002 12 00 00 |
|---|
A question or a specific configuration?
Contact us for a quote.